William Blair Has Bullish Forecast for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Research analysts at William Blair raised their Q2 2025 EPS estimates for Vertex Pharmaceuticals in a report released on Monday, July 14th. William Blair analyst M. Minter now expects that the pharmaceutical company will post earnings per share of $4.00 for the quarter, up from their previous forecast of $3.95. William Blair has a "Outperform" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

VRTX has been the subject of several other research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Leerink Partners reiterated a "market perform" rating and set a $503.00 target price (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Morgan Stanley decreased their target price on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a research note on Friday, June 20th. Fourteen research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $511.71.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX traded down $6.28 during trading hours on Tuesday, hitting $463.27. The company had a trading volume of 1,251,767 shares, compared to its average volume of 1,423,710. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a market cap of $118.97 billion, a PE ratio of -118.18 and a beta of 0.41. The business has a 50 day moving average of $448.13 and a 200-day moving average of $461.63.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $4.76 earnings per share.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Aries Wealth Management purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth $293,000. Polar Asset Management Partners Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $22,954,000. Brighton Jones LLC raised its position in shares of Vertex Pharmaceuticals by 45.0% in the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock worth $3,113,000 after buying an additional 1,994 shares during the period. GAMMA Investing LLC raised its position in shares of Vertex Pharmaceuticals by 25.1% in the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock worth $2,425,000 after buying an additional 1,005 shares during the period. Finally, APG Asset Management N.V. raised its position in shares of Vertex Pharmaceuticals by 189.7% in the 4th quarter. APG Asset Management N.V. now owns 359,285 shares of the pharmaceutical company's stock worth $139,724,000 after buying an additional 235,265 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.